共查询到7条相似文献,搜索用时 0 毫秒
1.
Jian Jiang Na Shen Tianyuan Ci Zhaohui Tang Zhen Gu Gao Li Xuesi Chen 《Advanced materials (Deerfield Beach, Fla.)》2019,31(44)
Tumor‐associated enzyme‐activated prodrugs can potentially improve the selectivity of chemotherapeutics. However, the paucity of tumor‐associated enzymes which are essential for prodrug activation usually limits the antitumor potency. A cooperative strategy that utilizes combretastatin A4 nanodrug (CA4‐NPs) and matrix metalloproteinase 9 (MMP9)‐activated doxorubicin prodrug (MMP9‐DOX‐NPs) is developed. CA4 is a typical vascular disrupting agent that can selectively disrupt immature tumor blood vessels and exacerbate the tumor hypoxia state. After treatment with CA4‐NPs, MMP9 expression can be significantly enhanced by 5.6‐fold in treated tumors, which further boosts tumor‐selective active drug release of MMP9‐DOX‐NPs by 3.7‐fold in an orthotopic 4T1 mammary adenocarcinoma mouse model. The sequential delivery of CA4‐NPs and MMP9‐DOX‐NPs exhibits enhanced antitumor efficacy with reduced systemic toxicity compared with the noncooperative controls. 相似文献
2.
Efficient and Targeted Suppression of Human Lung Tumor Xenografts in Mice with Methotrexate Sodium Encapsulated in All‐Function‐in‐One Chimeric Polymersomes 下载免费PDF全文
Weijing Yang Yan Zou Fenghua Meng Jian Zhang Ru Cheng Chao Deng Zhiyuan Zhong 《Advanced materials (Deerfield Beach, Fla.)》2016,28(37):8234-8239
3.
4.
5.
Minati Satpathy Liya Wang Rafal Zielinski Weiping Qian Malgorzata Lipowska Jacek Capala Gee Young Lee Hong Xu Y. Andrew Wang Hui Mao Lily Yang 《Small (Weinheim an der Bergstrasse, Germany)》2014,10(3):544-555
Despite advances in cancer diagnosis and treatment, ovarian cancer remains one of the most fatal cancer types. The development of targeted nanoparticle imaging probes and therapeutics offers promising approaches for early detection and effective treatment of ovarian cancer. In this study, HER‐2 targeted magnetic iron oxide nanoparticles (IONPs) are developed by conjugating a high affinity and small size HER‐2 affibody that is labeled with a unique near infrared dye (NIR‐830) to the nanoparticles. Using a clinically relevant orthotopic human ovarian tumor xenograft model, it is shown that HER‐2 targeted IONPs are selectively delivered into both primary and disseminated ovarian tumors, enabling non‐invasive optical and MR imaging of the tumors as small as 1 mm in the peritoneal cavity. It is determined that HER‐2 targeted delivery of the IONPs is essential for specific and sensitive imaging of the HER‐2 positive tumor since we are unable to detect the imaging signal in the tumors following systemic delivery of non‐targeted IONPs into the mice bearing HER‐2 positive SKOV3 tumors. Furthermore, imaging signals and the IONPs are not detected in HER‐2 low expressing OVCAR3 tumors after systemic delivery of HER‐2 targeted‐IONPs. Since HER‐2 is expressed in a high percentage of ovarian cancers, the HER‐2 targeted dual imaging modality IONPs have potential for the development of novel targeted imaging and therapeutic nanoparticles for ovarian cancer detection, targeted drug delivery, and image‐guided therapy and surgery. 相似文献
6.
Bo Yu Dalong Ni Zachary T. Rosenkrans Todd E. Barnhart Hao Wei Carolina A. Ferreira Xiaoli Lan Jonathan W. Engle Qianjun He Faquan Yu Weibo Cai 《Advanced materials (Deerfield Beach, Fla.)》2019,31(52)
Cerenkov radiation (CR) from radionuclides can act as a built‐in light source for cancer theranostics, opening a new horizon in biomedical applications. However, considerably low tumor‐targeting efficiency of existing radionuclides and radionuclide‐based nanomedicines limits the efficacy of CR‐induced theranostics (CRIT). It remains a challenge to precisely and efficiently supply CR energy to the tumor site. Here, a “missile‐detonation” strategy is reported, in which a high dose of p‐SCN‐Bn‐deferoxamine‐porphyrin‐PEG nanocomplex (Df‐PPN) is first adminstered as a CR energy receiver/missile to passively target to tumor, and then a low dose of the 89Zr‐labeled Df‐PPN is administrated as a CR energy donor/detonator, which can be visualized and quantified by Cerenkov energy transfer imaging, positron‐emission tomography, and fluorescence imaging. Based on homologous properties, the colocalization of Df‐PPN and 89Zr‐Df‐PPN in the tumor site is maximized and efficient CR energy transfer is enabled, which maximizes the tumor‐targeted CRIT efficacy in an optimal spatiotemporal setting while also reducing adverse off‐target effects from CRIT. This precise and efficient CRIT strategy causes significant tumor vascular damage and inhibited tumor growth. 相似文献
7.